

# Anti-IL-18 Reference Antibody (GSK 1070806)

Recombinant Antibody

Catalog # APR10256

## Product Information

---

|                          |                            |
|--------------------------|----------------------------|
| <b>Application</b>       | FC, Kinetics, Animal Model |
| <b>Primary Accession</b> | <a href="#">Q14116</a>     |
| <b>Reactivity</b>        | Human                      |
| <b>Clonality</b>         | Monoclonal                 |
| <b>Isotype</b>           | IgG1                       |
| <b>Calculated MW</b>     | 22326                      |

## Additional Information

---

|                           |  |
|---------------------------|--|
| <b>Target/Specificity</b> | IL-18  |
| <b>Endotoxin</b>          |  |
| <b>Conjugation</b>        | Unconjugated   |
| <b>Expression system</b>  | CHO Cell   |
| <b>Format</b>             | Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column. |

## Protein Information

---


|                          |  |
|--------------------------|--|
| <b>Name</b>              | IL18 ( <a href="#">HGNC:5986</a> )   |
| <b>Synonyms</b>          | IGIF, IL1F4  |
| <b>Function</b>          | Pro-inflammatory cytokine primarily involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses (PubMed: <a href="#">10653850</a> ). Upon binding to IL18R1 and IL18RAP, forms a signaling ternary complex which activates NF-kappa-B, triggering synthesis of inflammatory mediators (PubMed: <a href="#">14528293</a> , PubMed: <a href="#">25500532</a> , PubMed: <a href="#">37993714</a> ). Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells and natural killer (NK) cells (PubMed: <a href="#">10653850</a> ). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed: <a href="#">33883744</a> ). |
| <b>Cellular Location</b> | Cytoplasm, cytosol. Secreted. Note=The precursor is cytosolic (PubMed: <a href="#">33883744</a> ). In response to inflammasome-activating signals, cleaved and secreted (PubMed: <a href="#">33883744</a> , PubMed: <a href="#">37993712</a> , PubMed: <a href="#">37993714</a> ). Mature form is secreted and released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed: <a href="#">33883744</a> , PubMed: <a href="#">37993714</a> ). In contrast, the precursor form is not released, due to  |

the presence of an acidic region that is proteolytically removed by CASP1, CASP4 or CASP5 during maturation (PubMed:33883744, PubMed:37993714). The secretion is dependent on protein unfolding and facilitated by the cargo receptor TMED10 (PubMed:32272059).


## Tissue Location

[Isoform 2]: Expressed in ovarian carcinoma but undetectable in normal ovarian epithelial cells. Resistant to proteolytic activation by caspase-1 and -4


## Images



Anti-IL-18 Reference Antibody (GSK 1070806) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IL-18 Reference Antibody (GSK 1070806) is more than 95%, determined by SEC-HPLC.



Anti-IL-18 Reference Antibody (GSK 1070806)-induced FACS Blocking activity was evaluated using Hu IL-18R $\alpha$ -Hu IL-18R $\beta$ -HEK293-A8. The IC<sub>50</sub> was approximately 0.335  $\mu$ g/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.